BOSTON — Ocriplasmin may become the first pharmacologic option for patients with vitreomacular adhesion, according to two presentations here. "This drug has a very broad spectrum of application in ...

In a unanimous decision yesterday, the U.S. Food and Drug Administration’s Dermatologic and Ophthalmic Drugs Advisory Committee recommended approval of a 125-µg dose of ThromboGenics’ ocriplasmin for ...

Ocriplasmin, a truncated form of the serine protease plasmin, has proteolytic activity against 2 major components of the vitreoretinal interface: fibronectin and laminin. The efficacy and safety of ...

In two ancillary studies of two multi-center international clinical trials, the injectable drug ocriplasmin appears to improve vision among patients suffering from symptomatic vitreomacular adhesion ...

Vitreomacular adhesion (VMA) can lead to reduced visual acuity, metamorphopsia, photopsia, and micropsia. These symptoms are explained by vitreomacular traction (VMT) at the vitreomacular junction.

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that Health Canada has ...

ThromboGenics has received FDA approval for a drug to treat symptomatic vitreomacular adhesion, according to a news release. The drug, Jetrea, is approved to treat the eye condition, which can ...

JETREA (ocriplasmin) 2.5mg/mL intravitreal injection by ThromboGenics The FDA has approved Jetrea (ocriplasmin; ThromboGeneics) for the treatment of symptomatic vitreomacular adhesion (VMA), a ...

ThromboGenics NV announced new data from its pivotal ocriplasmin Phase 3 program including six month outcomes for the treatment of symptomatic vitreomacular adhesion (VMA) including macular holes. The ...

The aim of this study is to analyze the agreement between the classifications based on morphology and diameter of vitreomacular traction (VMT) syndrome, as well as to correlate the morphological ...

LOS ANGELES -- In two ancillary studies of two multi-center international clinical trials led by the University of Southern California (USC) Eye Institute, the injectable drug ocriplasmin appears to ...